ArticleCurrent organic chemistry2013
The Role of Mass Spectrometry in the "Omics" Era.
Article in Current organic chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- "Omics" and Postmortem Interval Estimation: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Faecal Metabolomics in Paediatric Inflammatory Bowel Disease: A Systematic Review.Journal of Crohn's & colitis · 2022Pooled it
- Specialized Metabolic Reprogramming in Plant Immunity: Biosynthetic Networks, Spatiotemporal Regulation, and Quantitative Defense.Plants (Basel, Switzerland) · 2026Review
- Application of the Mass Spectrometry-High-Throughput Technique Over the Immunohistochemical Analysis for Human Brain Tumor Diagnosis and Prognosis: Insights Into Biomarkers' Identification for the Case Study of Grade IV Astrocytomas and Meningiomas.Biomedical chromatography : BMC · 2025Article
- The Future of a Myriad of Accelerated Biodiscoveries Lies in AI-Powered Mass Spectrometry and Multiomics Integration.Journal of mass spectrometry : JMS · 2025Article
- The Latest Advances in Omics Technology for Assessing Tissue Damage: Implications for the Study of Sudden Cardiac Death.International journal of molecular sciences · 2025Review
- Systematic revelation and meditation on the significance of long exons using representative eukaryotic genomes.BMC genomics · 2025Article
- AHP DB: a reference database of proteins in the human aqueous humor.Database : the journal of biological databases and curation · 2024Article
- Isolation, Identification, Activity Evaluation, and Mechanism of Action of Neuroprotective Peptides from Walnuts: A Review.Nutrients · 2023Review
- Single-cell omic molecular profiling using capillary electrophoresis-mass spectrometry.Trends in analytical chemistry : TRAC · 2023Article
- Spatial Multiomics of Lipids, N-Glycans, and Tryptic Peptides on a Single FFPE Tissue Section.Journal of proteome research · 2022Article
- LC-MS Based Lipidomics Depict Phosphatidylethanolamine as Biomarkers of TNBC MDA-MB-231 over nTNBC MCF-7 Cells.International journal of molecular sciences · 2022Article
- Metabolomics in clinical and forensic toxicology, sports anti-doping and veterinary residues.Drug testing and analysis · 2022Review
- Role of lipidomics in assessing the functional lipid composition in breast milk.Frontiers in nutrition · 2022Review
- Intra-population differences of apolipoproteins in the aqueous humor.Lipids in health and disease · 2021Article
- MetFish: a Metabolomics Pipeline for Studying Microbial Communities in Chemically Extreme Environments.mSystems · 2021Article
- Detection of Aberrant Glycosylation of Serum Haptoglobin for Gastric Cancer Diagnosis Using a Middle-Up-Down Glycoproteome Platform.Journal of personalized medicine · 2021Article
- Biological Applications for LC-MS-Based Proteomics.Advances in experimental medicine and biology · 2021Article
- Innovative Approaches to Assess Intermediate Cardiovascular Risk Subjects: A Review From Clinical to Metabolomics Strategies.Frontiers in cardiovascular medicine · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mass spectrometry (MS) is one of the key analytical technology on which the emerging ''-omics'' approaches are based. It may provide detection and quantization of thousands of proteins and biologically active metabolites from a tissue, body fluid or cell culture working in a ''global'' or ''targeted'' manner, down to ultra-trace levels. It can be expected that the high performance of MS technology, coupled to routine data handling, will soon bring fruit in the request for a better understanding of human diseases, leading to new molecular biomarkers, hence affecting drug targets and therapies. In this review, we focus on the main advances in the MS technologies, influencing genomics, transcriptomics, proteomics, lipidomics and metabolomics fields, up to the most recent MS applications to meta-omic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.